InvestorsHub Logo
Followers 33
Posts 2840
Boards Moderated 2
Alias Born 10/24/2015

Re: None

Wednesday, 10/12/2022 7:25:05 PM

Wednesday, October 12, 2022 7:25:05 PM

Post# of 392
(OT) NKILT Therapeutics is developing a novel approach to target leukaemia's and solid tumours. The platform is allogeneic using armoured NK cells, focused on a new undisclosed target. The NKs will not only directly kill cancer cells, but will also activate innate immune cells and directly target the tumour's defence mechanisms.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News